DDInter94 DDInter172
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denileukin diftitox
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denileukin diftitox
Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Anakinra may lead to a major life threatening interaction when taken with Etanercept